Author

Sarah Spear

Imperial College LondonORCID 0000-0002-4306-3752Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Iain A. McNeishiD· 2 shared Adrián BenitoiD· 1 shared Adrian Llewellyn HarrisiD· 1 shared Alexandros SiskosiD· 1 shared Anja SchwenzeriD· 1 shared Anke M. NijhuisiD· 1 shared Audrey GérardiD· 1 shared Chandler Bray· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Iain A. McNeishORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The breast tumor microenvironment exploits eosinophil plasticity to suppress their anti-tumor activity

Zofia Varyova, Mathilde Pohin, Gracie J. Mead, Libby K. Jennings, Valeria da Costa, Sarah Spear, Iain A. McNeish, Anja Schwenzer, Adrian Llewellyn Harris, Audrey Gérard, Kim S. Midwood

This study shows that the breast tumor microenvironment transforms eosinophils into a less active state by reducing Ly6C expression, impairing their anti-tumor function, and that IFN stimulation can partially restore this phenotype.

bioRxiv · Jan 12, 2026 · PreprintImmunology

RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination

Michael Gruet, Yitao Xu, Lijie An, Yurui Ma, Cristina Domingo Balcells, Katie Tyson, Laila C. Evangelista, Sarah Spear, Yuewei Xu, Flora McKinney, Julia Babuta, Chandler Bray, Chiharu Wickremesinghe, Alexandros Siskos, Anke M. Nijhuis, , Hector C. Keun

This study identifies RAS/PI3K pathway mutations as a biomarker for sensitivity to PARP/NAMPT inhibitor combination therapy in epithelial ovarian cancer.

Communications Biology · Dec 19, 2025Peer-reviewedCancer Biology